Finland· FI-REL-REL16262
Theryttrex
A various therapeutic radiopharmaceuticals product containing yttrium (90y) chloride, registered in Finland by MDS Nordion S.A..
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Yttrium (90Y) chloride
- Manufacturer
- MDS Nordion S.A.
- Country
- Finland (FI)
- ATC code
- V10XX
- ATC class
- Various therapeutic radiopharmaceuticals
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Yttrium (90y) chloride in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e22d6153-a502-4bbc-82fd-3e6f0c684eab GET /v1/drugs/e22d6153-a502-4bbc-82fd-3e6f0c684eab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kantaliuos radioaktiivista lääkettä varten",
"route": null,
"ddd_unit": null,
"strength": "5.22 GBq/ml",
"atc_label": "Muut terapeuttiset radioaktiiviset lääkevalmisteet",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/02/245/001",
"fimea_rel_id": "REL16262",
"authorised_at": "2003-01-07"
}See everything about yttrium (90y) chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.